title: Intussusception, infection, and immunization: summary of a workshop on rotavirus.
abstract: This article summarizes the proceedings of a workshop sponsored by the National Institutes of Health and the National Vaccine Program Office, and held in Bethesda, Maryland, on January 21, 2000. The objective of the meeting was to focus research toward an understanding of the basis for the possible association between intussusception and the reassortant rhesus-human rotavirus vaccine tetravalent (RRV-TV). After numerous reports of intussusception after administration of RRV-TV, the manufacturers of this vaccine voluntarily withdrew it from the United States market. The American Academy of Pediatrics, the Advisory Committee on Immunization Practices, and the American Academy of Family Physicians also withdrew their original recommendations for administration of RRV-TV to children at 2, 4, and 6 months of age. These actions will have global implications for the prevention of morbidity and mortality attributable to rotavirus infection. Benefit-cost ratios for the use of RRV-TV will be substantially different in developing countries compared with developed countries. Therefore, extensive research is needed in both of these settings, to further our understanding of the epidemiology, pathogenesis, and pathology of both rotavirus disease and intussusception to enable optimal prevention. The workshop reviewed the current understanding of the possible association between RRV-TV and intussusception, as well as the possible association between a variety of viral infections and intussusception. The workshop also identified critical areas of research regarding this possible association. This research will be essential not only for the development of safe and effective rotavirus vaccines, but for the development of other oral vaccines as well.
authors.affiliation: National Vaccine Program Office, Atlanta, Georgia 30333, USA. lkombo@cdc.gov
authors.forename: L A
authors.initials: LA
authors.lastname: Kombo
authors.forename: M A
authors.initials: MA
authors.lastname: Gerber
authors.forename: L K
authors.initials: LK
authors.lastname: Pickering
authors.forename: C D
authors.initials: CD
authors.lastname: Atreya
authors.forename: R F
authors.initials: RF
authors.lastname: Breiman
mesh_terms: D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003906:Developing Countries; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence; D006801:Humans; D007223:Infant; D007443:Intussusception / Q000139:chemically induced* / Q000453:epidemiology; D012400:Rotavirus Infections / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States
chemical_list: D022243:Rotavirus Vaccines; C052014:rhesus rotavirus vaccine